- Home
- PPCB vs PRFX Comparison
PPCB vs PRFX Comparison
Compare PPCB & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPCB | PRFX |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | Australia | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PPCB | PRFX |
|---|---|---|
| Price | $0.12 | $2.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 31.2K |
| Earning Date | 02-17-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.58 |
| 52 Week High | $10.69 | $3.71 |
Technical Indicators
Market Signals| Indicator | PPCB | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 28.08 | 44.70 |
| Support Level | N/A | $1.28 |
| Resistance Level | $0.40 | $2.95 |
| Average True Range (ATR) | 0.02 | 0.22 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 7.02 | 10.00 |
Price Performance
Historical ComparisonAbout PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.